WFRF:(Abdi S)
Sökning: WFRF:(Abdi S) > Continuous versus i...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04713naa a2200673 4500 | |
| 001 | oai:gup.ub.gu.se/306495 | |
| 003 | SwePub | |
| 008 | 240528s2021 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/3064952 URI |
| 024 | 7 | a https://doi.org/10.1016/j.annonc.2021.07.0172 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Jerusalem, G4 aut |
| 245 | 1 0 | a Continuous versus intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. |
| 264 | 1 | b Elsevier BV,c 2021 |
| 520 | a Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy. In animal models, resistance was reversed with restoration of circulating estrogen level during interruption of letrozole treatment. This phase 3 randomized, open-label Study of Letrozole Extension (SOLE) studied the effect of extended intermittent letrozole treatment in comparison with continuous letrozole. In parallel, the SOLE estrogen sub-study (SOLE-EST) analyzed the level of estrogen during the interruption of treatment.SOLE enrolled 4884 postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer between December 2007 and October 2012 and among them, 104 patients were enrolled in SOLE-EST. They must have undergone local treatment and have completed 4-6 years of adjuvant endocrine therapy. Patients were randomized between continuous letrozole (2.5 mg/day orally for 5 years) and intermittent letrozole treatment (2.5 mg/day during 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all year 5).Intention-to-treat population included 4851 women in SOLE (n=2425 in intermittent and n=2426 in continuous letrozole groups) and 103 women in SOLE-EST (n=78 in intermittent and n=25 in continuous letrozole groups). After a median follow-up of 84 months, 7-year disease-free survival was 81.4% in intermittent group and 81.5% in continuous group (hazard ratio: 1.03, 95%CI: 0.91-1.17). Reported adverse events were similar in both groups. Circulating estrogen recovery was demonstrated within 6 weeks after the stop of letrozole treatment.Extended adjuvant endocrine therapy by intermittent administration of letrozole did not improve disease-free survival compared to continuous use despite the recovery of circulating estrogen level. The similar disease-free survival coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a breast cancer | |
| 653 | a endocrine treatment | |
| 700 | 1 | a Farah, S4 aut |
| 700 | 1 | a Courtois, A4 aut |
| 700 | 1 | a Chirgwin, J4 aut |
| 700 | 1 | a Aebi, S4 aut |
| 700 | 1 | a Karlsson, Per,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xkperd |
| 700 | 1 | a Neven, P4 aut |
| 700 | 1 | a Hitre, E4 aut |
| 700 | 1 | a Graas, M P4 aut |
| 700 | 1 | a Simoncini, E4 aut |
| 700 | 1 | a Abdi, E4 aut |
| 700 | 1 | a Kamby, C4 aut |
| 700 | 1 | a Thompson, A4 aut |
| 700 | 1 | a Loibl, S4 aut |
| 700 | 1 | a Gavilá, J4 aut |
| 700 | 1 | a Kuroi, K4 aut |
| 700 | 1 | a Marth, C4 aut |
| 700 | 1 | a Müller, B4 aut |
| 700 | 1 | a O'Reilly, S4 aut |
| 700 | 1 | a Gombos, A4 aut |
| 700 | 1 | a Ruhstaller, T4 aut |
| 700 | 1 | a Burstein, H J4 aut |
| 700 | 1 | a Rabaglio, M4 aut |
| 700 | 1 | a Ruepp, B4 aut |
| 700 | 1 | a Ribi, K4 aut |
| 700 | 1 | a Viale, G4 aut |
| 700 | 1 | a Gelber, R D4 aut |
| 700 | 1 | a Coates, A S4 aut |
| 700 | 1 | a Loi, S4 aut |
| 700 | 1 | a Goldhirsch, A4 aut |
| 700 | 1 | a Regan, M M4 aut |
| 700 | 1 | a Colleoni, M4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org |
| 773 | 0 | t Annals of Oncologyd : Elsevier BVg 32:10, s. 1256-1266q 32:10<1256-1266x 0923-7534 |
| 856 | 4 | u http://www.annalsofoncology.org/article/S0923753421024923/pdf |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/306495 |
| 856 | 4 8 | u https://doi.org/10.1016/j.annonc.2021.07.017 |
Hitta mer i SwePub
- Av författaren/redakt...
- Jerusalem, G
- Farah, S
- Courtois, A
- Chirgwin, J
- Aebi, S
- Karlsson, Per, 1 ...
- visa fler...
- Neven, P
- Hitre, E
- Graas, M P
- Simoncini, E
- Abdi, E
- Kamby, C
- Thompson, A
- Loibl, S
- Gavilá, J
- Kuroi, K
- Marth, C
- Müller, B
- O'Reilly, S
- Gombos, A
- Ruhstaller, T
- Burstein, H J
- Rabaglio, M
- Ruepp, B
- Ribi, K
- Viale, G
- Gelber, R D
- Coates, A S
- Loi, S
- Goldhirsch, A
- Regan, M M
- Colleoni, M
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Annals of Oncolo ...
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
